Anavex Life Sciences (AVXL) Earns “Buy” Rating from Noble Financial
Other equities research analysts also recently issued reports about the company. Zacks Investment Research downgraded Anavex Life Sciences from a buy rating to a hold rating in a research report on Friday, August 18th. ValuEngine downgraded Anavex Life Sciences from a hold rating to a sell rating in a research report on Thursday, September 28th. Finally, Maxim Group set a $15.00 price target on Anavex Life Sciences and gave the stock a buy rating in a research report on Thursday, October 12th.
Anavex Life Sciences (NASDAQ:AVXL) opened at $3.21 on Tuesday. Anavex Life Sciences has a 12-month low of $3.01 and a 12-month high of $6.64.
Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Monday, December 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). equities analysts forecast that Anavex Life Sciences will post -0.44 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. SNS Financial Group LLC acquired a new stake in Anavex Life Sciences during the 3rd quarter worth about $290,000. Northern Trust Corp grew its position in Anavex Life Sciences by 16.0% during the 2nd quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock worth $2,282,000 after purchasing an additional 59,069 shares during the period. Vanguard Group Inc. grew its position in Anavex Life Sciences by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock worth $8,528,000 after purchasing an additional 171,577 shares during the period. Virtu KCG Holdings LLC acquired a new stake in Anavex Life Sciences during the 2nd quarter worth about $186,000. Finally, Geode Capital Management LLC grew its position in Anavex Life Sciences by 16.8% during the 1st quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock worth $1,589,000 after purchasing an additional 39,934 shares during the period. 23.88% of the stock is currently owned by institutional investors.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.